Significant improvement seen in self-reported brain fog, concentration, working memory, processing speed, verbal memory, problem solving.

FDA adds a boxed warning to ferric carboxymaltose prescribing information, emphasizing severe low phosphate risks and mandatory monitoring protocols.

HealthDay News — Unintentional ingestion of recreational drugs increased substantially in US children younger than 6 years of age from 2000 to 2024, according to a study published online June 24 in ...

The phase 3 REMODEL-1/-2 trials demonstrated the superiority of remibrutinib vs teriflunomide in reducing annualized relapse rate in RMS patients.

HealthDay News — Lower adherence to blood pressure-lowering medication is associated with no benefit for preventing cardiovascular events, according to a study presented at the annual meeting of the ...

Phase 3 SURPASS-ET data support the expanded indication of ropeginterferon alfa-2b-njft as the first new FDA-approved essential thrombocythemia therapy in nearly 3 decades.

Effective atrial fibrillation management requires rate or rhythm control, anticoagulation based on risk scores, and lifestyle ...

Approval of the IL-12/23 antagonist in pediatric ulcerative colitis was supported by data from the phase 3 UNIFI Jr trial, demonstrating 52-week clinical remission and favorable tolerability.

Mimrylo is the first subcutaneous hepcidin mimetic approved to control hematocrit levels and reduce phlebotomy burden in patients with polycythemia vera.

A healthy lifestyle in early childhood is associated with a reduced risk for inflammatory bowel disease (IBD), according to a study published online August 24 i ...

Lisraya is the first oral dual TYK2/JAK1 inhibitor indicated for adults with dermatomyositis, demonstrating significant ...

The researchers found that the adjusted mean percentage change in body weight at the 24-month follow-up was −3.40% for the Mediterranean-style intervention and −3.51% for the control intervention. The ...